Competitive Salary: F. Hoffmann-La Roche AG: This position may be based out of Santa Clara, California, USA, with remote work locations possible in The United States.Impact HealthcareRoche Sequen Santa Clara, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionWe are seeking a talented and highly motivated Sub-Chapter lead for the Next Generation Sequencing (NGS) algorithms development team at th Santa Clara, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, is focused on developing a disruptive Next-Generation Sequencing (NGS) platform United States (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionThis position may be based out of Santa Clara, CA, USA, with remote work locations possible in The United States.Impact HealthcareRoche Se Santa Clara, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: Impact HealthcareRoche Sequencing is developing ground-breaking next-generation sequencing products that allow scientists/clinicians powerful new aven Santa Clara, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionThe OMNI Bioinformatics and Immunology departments at Genentech are seeking a highly motivated computational scientist to engage in therap San Francisco, California (US)

Competitive Salary: F. Hoffmann-La Roche AG: Impact HealthcareRoche Sequencing is not only changing science, but we are changing lives. Our software teams are laying the groundwork for the future Ottawa (Region), Ontario (CA)

Competitive Salary: F. Hoffmann-La Roche AG: As the Head of Assay Bioinformatics, Molecular Lab Applications you will play a key role in setting technical strategy and driving execution for devel United States (US)

Funding Opportunity PAR-22-227 from the NIH Guide for Grants and Contracts. The purpose of the NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence.

Funding Opportunity PAR-22-226 from the NIH Guide for Grants and Contracts. The purpose of the Research and Entrepreneurial Development Immersion (REDI): NIA Entrepreneurship Enhancement Award (R25) is to promote the development of entrepreneurial training programs that are designed to broaden the skillset of graduate students and postdocs, as well as early career master's, Ph.D., and Dr.P.H. scientists, in fields relevant to the mission of NIA, including aging and Alzheimer's disease (AD) research. The goal of this program is to prepare trainees for a wide range of career paths, including those that are outside the normal research environment.

Funding Opportunity PAR-23-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere. Projects must be consistent the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been most recently been described in NOT-OD-20-018.

Funding Opportunity PAR-22-224 from the NIH Guide for Grants and Contracts. This FOA will support creative educational activities that focus primarily on research skills development. . Although activities focused primarily on mentoring activities or professional skills development are not within the scope of this funding announcement, the informal mentoring activities and professional skills development that are usually associated with courses for research skills development are permitted.

Notice NOT-DK-22-026 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-22-028 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

Notice NOT-CA-22-121 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-22-030 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for a Coordinating Center for the Cancer Adoptive Cellular Therapy (Can-ACT) network. The Can-ACT network of research sites will advance collaborative and novel approaches for adoptive cell therapy for solid tumors, with an emphasis on the transition from preclinical testing and translational studies to early phase clinical trials. The Coordinating Center will provide leadership to the Can-ACT network, facilitate data sharing and collaboration, and coordinate clinical trial activities between research sites and the NCI.

Funding Opportunity RFA-CA-22-029 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

Funding Opportunity RFA-NS-23-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This FOA is not specific for any one or group within the AD/ADRD spectrum of disorders. Disorders, and includes genome editing therapies for: Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), Alzheimers Disease (AD) and Multiples Etiology Dementias (MED).

Funding Opportunity RFA-DK-22-013 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to invite applicationsfor for clinical centers for the continuation of the Drug-Induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA- DK-22-508) seeks to continue the Data Coordinating Center for DILIN. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, dietary and herbal supplements have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN throughout its publications has become the major source of information and progress in understanding the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease.

Funding Opportunity RFA-DK-22-508 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement is a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and build a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in Herbal and Dietary Supplements (HDS) implicated in liver toxicity. This RFA and companion [RFA-DK-22-013, Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 - Clinical Trial Optional)] will seek the continuation of the Data Coordinating Center and several Clinical Centers. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN through its publications has become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease.